Interpretation: The present study demonstrates the potential of 3′3′-cGAMP to induce HIV-1-specific CD8 + T cells with strong effector function from naïve cells via a strong type I IFN production and suggests that this STING ligand may be useful for AIDS vaccine and cure treatment.
Introduction

HIV-1-specific CD8
+ T cells are key players in the control of HIV-1 infections and cure treatment [1] [2] [3] [4] [5] [6] . In recent years, their central role in purging HIV-1 reservoirs has also become obvious [7] . In an in vitro model of latency, expanded HIV-1-specific CD8 + T cells from ARTtreated individuals were able to eliminate reactivated HIV-1-infected CD4 + T cells [8] . The induction of potent SIV-specific CD8 + T cells led to viral control and elimination of some SIV reservoirs in macaques vaccinated with a Rhesus CMV vector [9] . These studies have opened new therapeutic avenues where agents that reactivate latently-infected cells combine with immune interventions to induce the production of effective CD8 + T cells that can clear HIV-1 reservoirs in individuals on ART. Recent encouraging data show that the reduction in the viral reservoir upon treatment with TLR7 to reactive latently infected cells correlates with the magnitude of SIV-specific CD8 + T cell responses [10] . The induction of potent HIV-1-specific CD8 + T cell responses remains, therefore, a major objective to achieve a functional cure in the absence of treatment [11] . However, previous efforts to induce effective HIV-1-specific cellular immunity in human upon vaccination have failed [12, 13] , suggesting that the HIV-1-specific CD8 + T cells induced by the vaccines presented no benefit in preventing or controlling HIV-1 replication.
In recent years, several reports have emphasized the importance of functional or qualitative properties of CD8 + T cells for HIV-1 control [14, 15] . In particular, a strong expression of T-bet, along with effector molecules such as perforin and granzyme B whose synthesis it promotes, were shown to correlate with anti-viral efficacy [16] . Recently, the induction during the early days following an HIV-1 infection of CD8 + T cells displaying a high level of T-bet and perforin showed a direct benefit on HIV-1 reservoir seeding in vivo, thus providing a strong rationale for designing interventions aimed at inducing these potent responses against HIV-1 [17] .
The acquisition of such superior functional properties is thought to be crucially dependent on the priming of HIV-1-specific CD8 + T cells.
Pathogen recognition receptor (PRR) ligands enhance the priming process to elicit more robust adaptive immune responses [18] [19] [20] [21] . Among PRR ligands, pathogen-derived factors such as lipopolysaccharides (LPS), which is a ligand for TLR4, have been recognized as potent adjuvants that enhance the survival, effector capability, and homing of antigen-stimulated T cells [22] . It is known that LPS can also prime melanoma-specific T cells from naïve T cells [23] . Agonists for the innate sensor STING (stimulator of IFN genes) are novel and highly promising immunomodulators that are currently tested in clinical trials to improve immune surveillance and control of tumors [24] . Cyclic dinucleotides such as 3′3′-cGAMP and 2′3′-cGAMP directly bind to the transmembrane molecule STING, thereby activating the TBK1-IRF3-dependent signaling pathway to induce the robust production of type-I IFNs [25] . Type I IFNs have been shown to enhance CD8 + T cell effector function ex vivo by increasing their killing ability [26] [27] [28] [29] . The link between type I IFN and HIV-1 infection have been intensively studied [30] . Type I IFN are reported to induce anti-HIV-1 effects by enhancing the expression of anti-viral genes such as APOBEC3G, thetherin, and SAM domain, suggesting that IFN-I responses are detrimental for viral replication and spread [31] . Moreover, administration of IFN-α to HIV-1-infected patients with Kaposi's sarcoma resulted in lower viral load and higher CD4/CD8 T cell ratio compared to placebo [32] . Several studies showed that IFN-α-treated patients had a less severe CD4 decline, lower HIV-1 load, fewer opportunistic infections, and slower disease progression with increased frequency of activated CD8 T cells [33] . Thus, previous studies imply that type I IFN also enhances HIV-1-specific T cell functions. However, it remains unclear whether STING ligands can be used as adjuvants to induce HIV antigen specific T cells. In humans, a recent study actually suggested a rather inhibitory effect of the STING pathway on adaptive immune responses [34] . Here we used an in vitro approach to prime HIV-1-specific CD8 + T cells from unfractionated peripheral blood mononuclear cells (PBMCs) derived from HIV-1-uninfected individuals. We investigated the ability of 3′3′-cGAMP to prime functional HIV-1-specific CD8 + T cells from naïve cells and compared it to that of LPS, which can elicit melanomaspecific T cells from naïve cells but does not induce type I IFN production [35] .
Materials and methods
Subjects
Fifteen HLA-A*24:02 + HIV-1-seronegative individuals were recruited for this study, which was approved by the Ethical Committee of Kumamoto University, Japan. Written informed consent was obtained from all subjects according to the Declaration of Helsinki. Blood mononuclear cells (PBMCs) were separated from whole blood by the use of Ficoll-Paque PLUS.
Cell lines
C1R cells expressing HLA-A*24:02 (C1R-A*2402) were generated by transfecting C1R cells with HLA-A*24:02 genes as described previously [36] . These cells were cultured in RPMI 1640 medium (invitrogen) containing 5% fetal calf serum (FCS, R5) and 0.15 mg/ml hygromycin B.
In vitro priming of naïve HIV-1-specific CD8 + T cells
Naïve precursors specific for HLA-A*24:02-RF10 were primed in vitro by using an accelerated dendritic cell co-culture protocol [37, 38] . On day 0, frozen-thawed PBMCs of HLA-A*24:02 + HIV-1-seronegative individuals were suspended at 5 × 10 6 cells/well in 24-well tissue culture plates containing AIM-V medium (Invitrogen) supplemented with Flt3L (50 ng/ml; R&D Systems). After 24 h, 500 μl of AIM-V medium supplemented with RF10 peptide (10 μM) and TLR4 ligand LPS (0.1 μg/ml; InvivoGen) or STING ligand 3′3′-cGAMP (10 μg/ml; InvivoGen) were added, and then FCS were further added to 10% by volume per well on day 2. On day 10, the cells were collected and then stained with RF10-tetramers.
Tetramer staining
HLA-A*24:02-RF10 peptide complexes (RF10-tetramer) were generated as previously described [39] . RF10-specific CD8 + T cells were stained with PE-conjugated RF10 tetramers at 37°C for 30 min. After 2 washes with R5, the cells were stained with 7-AAD (BD Pharmingen) at room temperature for 10 min followed by incubation with APCconjugated anti-CD8 mAb (DAKO, Denmark) at 4°C for 30 min. Finally, the cells were washed twice with R5 and analyzed by using a FACS Cant II. Primed T cells unstained with tetramer were used as a negative control to determine gating of the tetramer + population. The tetramer + population was determined based on the gating of the negative control (b0% of tetramer + cells).
Research in context
Evidence before this study 
Implications of all the available evidence
This study demonstrates the potential application of the STING ligand 3′3′-cGAMP to induce highly-functional HIV-1-specific CD8 + T cells from naïve cells. The STING ligand 3′3′-cGAMP may be useful for AIDS vaccine development to prevent HIV-1 infection, and for cure strategy to eradicate latently-infected cells. with the peptide at 100 nM in R10, containing 20 ng/ml of human rIL-2 (ProSpec), and 2.5% phytohemagglutinin soup). After 2 weeks culture, RF10-specific CD8 + T cells were used in functional assays after their purity was confirmed by flow cytometry analysis using tetramers. An HLA-A*24:02-restricted RF10-specific CTL clone (CTL52) from an HIV-1-infected individual was generated as previously described [40] and used as a positive control.
2.6. Intracellular staining of perforin, granzyme B, and T-bet RF10-specific CD8 + T cell lines and the CTL52 CTL clone were stained with PE-conjugated RF10 tetramer, 7AAD, and APC-conjugated or Pacific blue-conjugated anti-CD8 mAb (BD Pharmingen), fixed with 4% paraformaldehyde solution, and then rendered permeable with 0.1% saponin buffer. Thereafter, the cells were stained with Alexa647-labeled anti-Granzyme B (BD Pharmingen) and Alexa488-labeled anti-Per (BD Pharmingen) or V450-labeled anti-T-bet (BD Horizon). Intracellular staining for T-bet was performed by using a Transcription Factor Buffer Set (BD Pharmingen) according to the manufacturer's instructions. All stained cells were analyzed on a FACS Canto II, on the same days. To clarify whether the CD8 + T cell lines had high expression level of granzyme B, perforin, and T-bet, we compared the expression level of these molecules in CD8 + T cell lines and in the clone, and calculated relative MFI ratio as: MFI for the CD8 + T cell lines/that for the clone.
HIV-1 replication suppression assay
The ability of RF10-specific CD8 + T cell lines to suppress HIV-1 replication was measured as described previously [40] . CD4 + T cells iso- 
Cytokine production and polyfunctionality
RF10-specific CD8 + T cell lines were stimulated with C1R-A*2402 cells prepulsed with 100 nM RF10 peptide for 2 h at 37°C. Brefeldin A (10 μg/ml, Sigma-aldrich) was added, and the cells were then incubated further for 4 h at 37°C. Subsequently, they were stained with 7-AAD and Pacific blue-conjugated anti-CD8 mAb, fixed with 4% paraformaldehyde solution at 4°C for 20 min, and then made permeable with 0.1% saponin buffer at 4°C for 10 min. Thereafter, the cells were stained with FITCconjugated anti-IFN-γ mAb (BD Pharmingen), APC-conjugated IL-2 mAbs (BD Pharmingen), PE-Cy7-conjugated TNF-α mAbs (BD Pharmingen), and APC-H7-conjugated MIP-1β mAbs (BD Pharmingen). Nonspecific production of cytokines was excluded by subtracting the data of the negative control, which was the same sample stimulated 
Phenotypic analysis
RF10-specific CD8 + T cell lines were stained with APC-conjugated tetramers at 37°C for 30 min. After 2 washes, the cells were stained with PE-Cy7-conjugated anti-CCR7 (BD Pharmingen) and 7-AAD at room temperature for 10 min followed by AmCyan-conjugated anti-CD8 (BD Biosciences), Pacific blue-conjugated anti-CD3 (BD Pharmingen), PE-conjugated anti-CD28 (BD Pharmingen), APCeFluor® 780-labeled CD27 (Invitrogen), and FITC-conjugated anti-CD45RA (BD Pharmingen) at 4°C for 30 min. The stained cells were analyzed by using a FACS Canto II.
Type I IFN and type II IFN measurements
Frozen-thawed PBMCs of HIV-1-seronegative individuals were suspended at 5 × 10 6 cells/well in 24-well tissue culture plates containing AIM-V medium supplemented with LPS (0.1 μg/ml) or 3′3′-cGAMP (10 μg/ml). After 24 h, supernatants were collected; and then the concentrations of IFN-α, −β, −ω, and -γ were measured by ELISA (Invitrogen).
Blocking of type I IFN in vitro priming
On day 0, frozen-thawed PBMCs of HLA-A*24:02 + HIV-1-seronegative individuals were suspended at 5 × 10 6 cells/well in 24-well tissue culture plates containing AIM-V medium (Invitrogen) supplemented with Flt3L (50 ng/ml; R&D Systems). For blocking experiment of type I IFN, mixture of antibodies (PBL Assay Science) directed against an human type I IFN receptor and several type I IFNs (IFN-α, −β, −ω, −κ, and ε) was added to the culture cells 30 min before stimulation of RF10 peptide (10 μM) and LPS or 3′3′-cGAMP (10 μg/ml; InvivoGen) at day 1. FCS was further added to 10% by volume per well on day 2. On day 10, the cells were collected and then stained with RF10-tetramers.
TCR binding avidity
RF10-specific CD8 + T cell lines were stained with various concentrations of PE-conjugated RF10 tetramers (0, 0.1, 1, 10, 100 nM) at 37°C for 30 min. After 2 washes with R5, the cells were stained with 7-AAD (BD Pharmingen) at room temperature for 10 min followed by incubation with APC-conjugated anti-CD8 mAb (DAKO, Denmark) at 4°C for 30 min. TCR avidity between LPS-primed T cell lines and 3′3′-cGAMP T cell lines was compared in terms of TCR binding index. TCR binding index was calculated as follow: (EC 50 of primed T cell line/EC 50 of control clone CTL52).
TCR clonotype analysis
RF10-specific CD8 + T cell lines established from HIV-1-seronegative individuals were stained with PE-conjugated tetramers, APCconjugated anti-CD8 mAb, and 7-AAD; and then the tetramer + CD8 + 7-AAD − cells were sorted by using a FACS Aria. The sorted single cells were plated into each well of a 96-well plate (total 48 wells per cell line). For samples from sorted single RF10-specific CD8 + T cells, unbiased identification of TCR αβ chain usage was assessed as previously described [42] . Using this method, PCR success rates of 47% and 62% on average were obtained for TCRα and TCRβ chains respectively [42] . All PCR amplifications of full-length TCRα/β chains were sequenced (8-22 cells were sequenced per line). TCR gene usage was determined with reference to the ImMunoGeneTics (IMGT) database [43] .
Statistical analysis
Univariate statistical analyses were performed using Prism software (GraphPad). Groups were compared using a paired t-test or MannWhitney U tests. Correlations were determined using the Spearman rank test. P values b.05 were considered significant.
Results
In vitro priming of HIV-1-specific CD8
+ T cells from naïve cells (Fig. 1c) . The binding ability of the tetramer varied among these T cell lines (Fig. 1c) , suggesting that these T cell lines expressed different TCRs or the same TCR with different affinity. We used these T cell lines for functional assays.
3.2. Ability of 3′3′cGAMP-primed RF10-specific CD8 + T cell lines to suppress
HIV-1 replication
To investigate the efficacy of RF10-specific CD8 + T cells primed from naïve cells to suppress replication of HIV-1, we measured the ability of LPS-primed RF10-specific T cell lines or 3′3′cGAMP-primed ones to suppress HIV-1 replication in primary CD4 + T cells infected with NL4-3, and compared to that of HLA-A*24:02-restricted RF10-specific CTL clone (CTL52) presenting a strong HIV suppression capacity [40, 44] . Despite successful priming, all LPS-primed RF10-specific T cell lines presented a poor HIV suppression capacity ( Supplementary Fig. 1 ). In contrast, 3′ 3′-cGAMP-primed RF10-specific CD8 + T suppressed the replication of HIV-1 ( Supplementary Fig. 1 ). 3′3′cGAMP-primed RF10-specific T cell lines exhibited a significantly higher viral suppression ratio than LPSprimed ones (Fig. 2a) . Five out of the nine 3′3′cGAMP-primed T cell lines showed a N 0.5 ratio, whereas all of the nine LPS-primed ones showed a b 0.2 ratio (Fig. 2a) . The former T cell lines showed higher viral suppression capacity than the latter T ones from the same individual in six out of seven cases (Fig. 2b) . Taken together, these results suggest that 3′3′-cGAMP effectively primed RF10-specific T cells with a much stronger viral suppression ability than LPS-primed ones. Fig. 2a ). There was no significant difference in this index between LPS-primed RF10-specific T cell lines and 3′ 3′-cGAMP-primed ones (Fig. 3a) . We also observed no correlation between viral suppression ability and TCR avidity in LPS-primed T cell lines and 3′3′-cGAMP-primed ones (Fig. 3b) . These results suggest that TCR avidity was not a critical factor for viral suppression ability of primed T cell lines but that other factors may have critically contributed to strong viral suppression ability in this setting. Despite TCR repertoire diversity and flexibility, HIV-specific CD8 + T cell populations are frequently characterized by specific clonotypic immunodominance or even public TCRs in HIV-1-infected individuals [44] [45] [46] [47] [48] [49] . For example, Nef RF10-specific CD8 + T cells having TRVD1*01/TRBV28*01 clonotype were predominantly elicited among chronically HIV-1-infected HLA-A*24:02 + Japanese individuals [44, 46] . These findings suggest that a particular TCR clonotype may also be recruited among RF10-specific CD8 + T cells primed with LPS or 3′3′-cGAMP from naïve T cells. We therefore analyzed the TCR clonotype of LPS-primed RF10-specific CD8 + T cell lines and 3′3′-cGAMP-primed ones at the single-cell level to clarify whether these 2 different ligands selected the same T cell clones or not. Except for 1 donor (U-46), different TCR clonotypes were found between LPSprimed RF10-specific CD8 + T cells and 3′3′-cGAMP-primed ones established from the same donors ( Fig. 3c and Supplementary Fig. 2b ). This TCR repertoire diversity highlights the random selection of antigen-specific clonotypes among a polyclonal naïve T cell population upon priming, indicating that 3′3′-cGAMP did not preferentially select T cells expressing high-functioning TCRs. [50] . To investigate the differentiation stage of the primed T cell lines, we analyzed their phenotype by using these four markers (Fig. 4a) . The control CTL clone expressed the CD27 In contrast, both LPS-primed T cell lines and 3′3′cGAMP-primed ones presented the late effector memory phenotype ( Fig. 4a and b) , although some of the lines showed the effector phenotype. These findings indicate that T cell lines primed with these ligands had differentiated to a similar stage. We next investigated the ability of these T cell lines to produce different cytokines or chemokines (IFN-γ, IL-2, TNF-α and MIP-1β). The RF10-specific CTL clone 52 established from an HIV-1-infected HLA-A*24:02 + individual was used as control for further analysis, since this clone had a strong ability to suppress HIV-1 replication [40, 44] . Both LPS-primed T cell lines and 3′3′cGAMP-primed ones had the ability to produce all of these cytokines and chemokine in response to RF10 peptide, although no difference was found in their production between these cells (Supplementary Fig. 3 ). However, overall 3′3′-cGAMPprimed T cell lines showed significantly a higher polyfunctionality index than LPS-primed ones ( Fig. 4c and Supplemental Table 1 ), suggesting that 3′3′-cGAMP primed more polyfunctional CD8 + T cells than did LPS.
Differentiation status and cytokine production of HIV
− CD28 − CD45RA − CCR7 − effector phenotype.
Expression of cytolytic effector molecules in HIV-1-specific CD8 + T cells primed with 3′3′-cGAMP
To investigate the expression level of cytolytic effector molecules in T cells primed with 3′3′-cGAMP or LPS, we measured intracellular granzyme B and perforin as well as T-bet in the RF10-specific CD8 + T cell lines (Fig. 5a ). 3′3′-cGAMP-primed RF10-specific T cell lines displayed higher expression levels of granzyme B (P b .05), perforin (P b .01), and T-bet (P = .06) than LPS-primed ones ( Fig. 5b and Supplementary  Fig. 4) . Thus, LPS-primed T cell lines had not been fully differentiated into effector T cells expressing sufficient amounts of granzyme B and perforin. We found a significant positive correlation between viral suppression ability and perforin expression in the primed T cell lines (Fig. 5c) . There was also a clear trend when considering 3′3′-cGAMPprimed CD8 + T cells only ( Supplementary Fig. 5 ). The expression level of perforin appears therefore as a key factor for viral suppression capacity of 3′3′-cGAMP-primed RF10-specific T cells. This is in line with previous results on HCMV or EBV-specific T cells [50] . Overall, 3′3′-cGAMP promoted the induction of HIV-1 suppressive CD8 + T cells, not through the selection of naïve T cells with high TCR avidity, but by enhancing intrinsic functional properties of primed T cells.
Correlation between IFN production and effector functions of 3′3′-cGAMP-primed CD8 + T cells
To get mechanistic insights underlying effective priming of HIV-1-specific CD8 + T cells with strong effector functions in the presence of 3′3′-cGAMP, we investigated the production of IFN from HIV-1-seronegative individuals PBMCs. We stimulated PBMCs from 13 HIV-1-seronegative individuals with LPS or 3′3′-cGAMP, and then measured the production levels of type I IFN (IFN-α, −β, and -ω) and type II IFN (IFN-γ). 3′3-'cGAMP induced significantly higher level of IFN production than LPS, except in the case of IFN-γ production (Fig. 6a) . These results indicate that a stronger type I IFN production was triggered by 3′ 3′-cGAMP than by LPS during T-cell priming. To investigate the effect of type I IFN production on the effector function of 3′3′-primed HIVspecific CD8 + T cells, we further examined the correlation between IFN production induced by 3′3′-cGAMP and the expression level of cytolytic effector molecules or viral suppression ability of 3′3′-cGAMPprimed RF10-specific T cell lines established from 8 individuals. The expression level of perforin in 3′3′-GAMP-primed T cells correlated positively with the production of all type I IFNs, and the one of granzyme B was significantly correlated with IFN-β production levels (Fig. 6b ). Viral suppression capacity was also significantly correlated with IFN-β and showed a trend for a positive correlation with IFN-α (Fig. 6b) .
To clarify the effect of type I IFN on induction of functional T cells, we further investigated the blocking effect of anti-type I IFN blocking antibodies on the priming of functional T cells. The presence of type I IFN blocking antibodies during priming yielded a trend towards lower frequency of the 3′3′-cGAMP-primed T cells, whereas there was no effect of these antibodies on LPS-primed ones (Fig. 7a) . This suggests that type I IFNs play a role in the induction of the specific T cells from naïve cells. The expression levels of granzyme B and perforin in 3′3′-cGAMP-primed HIV-1-specific T cell lines were significantly decreased in the presence of anti-type I IFN blocking antibodies, whereas levels in LPS-primed cell lines were not affected (Fig. 7b) . These results support the idea that type I IFN production induced by 3′3′-cGAMP is a key factor for induction of functional T cells from naïve T cells. Type I IFN has been reported to promote the expression level of cytolytic molecules and cytotoxic effector function in CD8 + T cells [26] [27] [28] [29] . Given these reports and the present findings, we propose that high-level of type I IFN production induced by 3′3′-cGAMP is the mechanism by which the effector functions of HIV-1-specific CD8 + T cells primed from naïve cells was enhanced.
Discussion
We demonstrated that STING ligand 3′3′-cGMAP elicited functional HIV-1-specific CD8 + T cells expressing high levels of perforin and granzyme B, although TLR4 ligand LPS did not do so. STING ligands are known to promote cross-presentation, which is key for cross-priming and effective induction of CD8 + T cells [51] ; and they also generate particularly strong type I IFN responses [52] that lead directly to up-regulated expression of T-bet and subsequently to perforin and granzyme B production in primed CD8 + T cells [26, 53] . Indeed, type I IFN signaling drives the acquisition of the cytolytic function of CD8 + T cells [27] [28] [29] . A mouse model study showed that IFN-α and -β provided signal-III directly to CD8 + T cells via a STAT4-dependent pathway to develop cytolytic function and production of IFN-γ [53] . The present study demonstrated that 3′3′-cGAMP produced a much higher level of type I IFN than did LPS and that the production level of this IFN was correlated with the expression levels of perforin and granzyme B in 3′3′-cGAMPprimed T cells. These results suggest that robust type I IFN production induced by 3′3′cGAMP promoted the priming of HIV-1-specific CD8 + T cells with strong cytolytic effector function. Therefore, rather than acting on signal I between T cells and APCs (i.e., TCR-pMHC signaling), STING ligands exploited signal III (i.e., stimulatory cytokines) in order to boost intrinsic cellular factors such as perforin in T cells, thus enhancing their cytolytic functions. Considering the importance of TCR avidity for CD8 + T cell effector functions and efficacy [45] , we speculated that the STING ligand might have promoted the selection of HIV-1-specific T cell clonotypes having high-avidity TCRs. However, this was not the case, as there was no significant difference in TCR avidity between 3′3′-cGAMP-primed RF10-specific T cells and LPS-primed ones, as well as no direct correlation between TCR avidity and HIV-1 suppressive capacity. Clonotypic analyses at the single-cell level showed that a variety of TCR clonotypes were recruited within HIV-1-specific CD8 + T cell population primed under different adjuvant conditions from the same or different donors, indicating the random selection of antigen-specific clonotypes among a polyclonal naïve T cell population upon priming. Of note, 1 clonotype (TRAV1*01/ TRBV19*01) found in a donor (U-46) primed T cell population, was also previously identified in a RF10-specific CD8 + T cell population from a chronically HIV-1-infected patient [44, 46] , illustrating the connection between in vitro and in vivo priming of HIV-1-specific CD8 + T cells.
We also showed that although seemingly polyfunctional HIV-1-specific CD8 + T cells could be successfully primed with LPS, they actually lacked important functional attributes of efficacy such as perforin expression and the ability to suppress HIV-1 replication. This is reminiscent of the immunogenicity but poor efficacy of previous T cell-based HIV-1 vaccines in clinical trials [12, 13] and implies that further developments are needed to induce more effective CD8 + T cells able to impact positively vaccination outcomes. Our findings highlight the potential of 3′3′-cGAMP to induce potent CD8 + T cell immunity against HIV-1.
STING ligands may therefore present an interest in HIV vaccine development. Although encouraging, the present work represents only a preliminary step towards the potential use of cGAMP as an adjuvant to induce effective HIV-1 specific CD8 + T cells, as multiple issues need to be solved before envisaging clinical trials. First, the present study is in vitro, and may not reflect the induction of T-cells in vivo, where the APCs and environment in lymphoid tissue differ. Second, our study focuses primarily on the induction of T cells with immediate effector functions, while the goal of vaccination is generally on inducing long-lived cells with strong regenerative capacity. Further studies are therefore needed to address these issues, as well as the homing of primed HIV-1-specific T cells to lymphoid tissues in vivo, or the selection of HIV-1 protective epitopes. Our previous studies demonstrated that CD8 + T cells specific for conserved Gag and Pol regions have strong ability to suppress HIV-1 replication in vivo and in vitro [54] [55] [56] , suggesting that these T cells may have ability to eradicate the latent viral reservoir. STING ligands may therefore be incorporated into nanoparticles such as amphiphiles or polymers as delivery agents, together with conserved and protective HIV-1 epitopes, in order to generate effective anti-HIV-1 immunity in lymphoid tissues. In association with molecules able to reactivate the latent reservoir, the immediate immuno-stimulatory potential of cGAMP may be crucial to eradicate efficiently latently HIV-1 infected cells towards a functional cure of HIV-1 + patients [57] .
To conclude, we present here a reliable in vitro approach to prime functional human CD8 + T cells specific for an HIV-1 antigen. STING ligands appear to have a strong ability to prime HIV-1-specific CD8 + T cells with strong effector functions enhanced by high-level production of type-I IFN. Our findings represent an important methodological advance, enabling for the first time the study of HIV-1-specific CD8 + T cell priming outside the complex setting of a vaccine clinical trial towards the functional cure and potentially the prevention of HIV-1 infection. The present work paves the way for the use of potent adjuvants such as STING ligands in the fight against HIV-1.
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